Oncology · 2 h ago
GALE loss increases Vγ9Vδ2 T-cell killing of tumors in preclinical models
A genome-wide CRISPR screen identified the metabolic enzyme GALE as a tumor-cell factor that limits Vγ9Vδ2 T-cell-mediated killing. In mouse models and colorectal cancer patient-derived organoids, GALE loss enhanced tumor killing, with glycosylation changes affecting inhibitory and activating immune-receptor interactions.
- CRISPR screening identified GALE as a tumor-intrinsic checkpoint.
- GALE-associated glycosylation favored inhibitory receptor interactions.
- GALE loss enhanced T-cell killing in preclinical models.
- Clinical efficacy and safety remain unestablished.
Vγ9Vδ2 T cells can recognize tumor cells independently of HLA, but their therapeutic activity is limited. In a study published in *Nature Cancer*, researchers used a genome-wide CRISPR screen to identify tumor-cell genes that affect Vγ9Vδ2 T-cell killing. The screen implicated UDP-galactose 4-epimerase (GALE), an enzyme involved in nucleotide-sugar metabolism and protein glycosylation.
Mechanistic analyses indicated that GALE promotes complex N-glycosylation of CD155 and CEACAM1. This favored interactions with the inhibitory receptors TIGIT and TIM3, while limiting CD155 binding to the activating receptor CD226. Loss of GALE enhanced Vγ9Vδ2 T-cell-mediated tumor killing in multiple mouse models and colorectal cancer patient-derived organoids.
The findings point to GALE and related receptor–ligand interactions as potential targets for improving antitumor activity of these T cells. The evidence is preclinical: the supplied report describes mouse models and organoids, not clinical treatment outcomes. It does not establish whether targeting GALE is safe or effective in patients, or whether the findings generalize beyond the models studied.
In practice
The findings identify tumor-cell GALE and its effects on CD155 and CEACAM1 glycosylation as possible ways to influence Vγ9Vδ2 T-cell antitumor activity. However, the evidence described is preclinical, comprising mouse models and colorectal cancer patient-derived organoids; the source reports no clinical treatment outcomes or evidence that inhibiting GALE is safe or effective in patients. These results do not support changing current cancer treatment.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Cancer: GALE is a tumor-intrinsic checkpoint of Vγ9Vδ2 T cell-mediated killing ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.